Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ivabradine

FDA-approved product (solution, oral), marketed as Corlanor, Ivabradine Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ivabradine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cardiac preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ivabradine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ivabradine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Heart Rate Controller in Computed Tomography Coronary Angiography

    NCT05261464 · start 2021-01-30

    Registered record
    Registry ID
    NCT05261464
    Conditions
    Heart Rate; Coronary Computed Tomography Angiography
    Interventions
    Metoprolol tartrate; Ivabradine; Diltiazem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-01-30
    Completion
    2022-06-30
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Rate; Coronary Computed Tomography Angiography
    InterventionMetoprolol tartrate; Ivabradine; Diltiazem
    PhasePhase 4
    Registry statusUnknown

  • Ivabradine Versus Propranolol for Induced Hypotension in Endoscopic Sinus Surgery

    NCT04580342 · start 2020-10-15

    Registered record
    Registry ID
    NCT04580342
    Conditions
    Hypotension
    Interventions
    oral Ivabradine; oral Propranolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-15
    Completion
    2021-01-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypotension
    Interventionoral Ivabradine; oral Propranolol
    PhasePhase 2
    Registry statusUnknown

  • PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery

    NCT04436016 · start 2020-10-05

    Registered record
    Registry ID
    NCT04436016
    Conditions
    Myocardial Injury; Myocardial Ischemia
    Interventions
    Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-10-05
    Completion
    2022-01-11
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Injury; Myocardial Ischemia
    InterventionIvabradine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Ivabradine in Patients With Congestive Heart Failure

    NCT04448899 · start 2020-06-01

    Registered record
    Registry ID
    NCT04448899
    Conditions
    Congestive Heart Failure
    Interventions
    Ivabradine Oral Tablet; Blacebo plus standard treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-01
    Completion
    2021-02-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure
    InterventionIvabradine Oral Tablet; Blacebo plus standard treatment
    PhasePhase 4
    Registry statusCompleted

  • Ivabradine in Cirrhotic Cardiomyopathy

    NCT04111133 · start 2020-01-01

    Registered record
    Registry ID
    NCT04111133
    Conditions
    Cirrhotic Cardiomyopathy; Left Ventricular Dysfunction; Cirrhosis, Liver; Portal Hypertension
    Interventions
    Betablocker + ivabradine; Betablocker
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2024-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhotic Cardiomyopathy; Left Ventricular Dysfunction; Cirrhosis, Liver; Portal Hypertension
    InterventionBetablocker + ivabradine; Betablocker
    PhaseNot applicable
    Registry statusUnknown

  • Ivabradine for Rate Control in Permanent Atrial Fibrillation

    NCT03987204 · start 2019-06-15

    Registered record
    Registry ID
    NCT03987204
    Conditions
    Atrial Fibrillation; Atrial Fibrillation, Persistent
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-15
    Completion
    2019-09-17
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Atrial Fibrillation, Persistent
    InterventionIvabradine
    PhasePhase 1
    Registry statusCompleted

  • Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

    NCT03650205 · start 2019-01-22

    Registered record
    Registry ID
    NCT03650205
    Conditions
    Neoplasms; Heart Failure; Cardiotoxicity; Chemotherapy Effect; Oncology
    Interventions
    Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-22
    Completion
    2021-12-01
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Heart Failure; Cardiotoxicity; Chemotherapy Effect +1 more
    InterventionIvabradine; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

    NCT03619187 · start 2018-11-02

    Registered record
    Registry ID
    NCT03619187
    Conditions
    Heart Transplantation, Elevated Resting Heart Rate
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-11-02
    Completion
    2020-02-19
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplantation, Elevated Resting Heart Rate
    InterventionIvabradine
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

    NCT04308031 · start 2018-08-26

    Registered record
    Registry ID
    NCT04308031
    Conditions
    Atrial Fibrillation; Ivabradine; Heart Failure
    Interventions
    Ivabradine 5 mg [Corlanor]; Digoxin 0.25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-08-26
    Completion
    2020-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Ivabradine; Heart Failure
    InterventionIvabradine 5 mg [Corlanor]; Digoxin 0.25 mg
    PhasePhase 3
    Registry statusUnknown

  • Effect of Ivabradine on Exercise Capacity After Heart Transplantation

    NCT03405831 · start 2018-04-17

    Registered record
    Registry ID
    NCT03405831
    Conditions
    Cardiac Allograft Vasculopathy; Transplanted Heart Complication
    Interventions
    Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-04-17
    Completion
    2019-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Allograft Vasculopathy; Transplanted Heart Complication
    InterventionIvabradine; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers

    NCT03485482 · start 2018-03-01

    Registered record
    Registry ID
    NCT03485482
    Conditions
    Cardiovascular Diseases
    Interventions
    Bisoprolol; Ivabradine; combination of Ivabradine and bisoprolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2018-03-23
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionBisoprolol; Ivabradine; combination of Ivabradine and bisoprolol
    PhasePhase 3
    Registry statusCompleted

  • Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

    NCT03137537 · start 2018-02-27

    Registered record
    Registry ID
    NCT03137537
    Conditions
    Lymphoma; Autonomic Imbalance; Cancer Survivorship
    Interventions
    Ivabradine; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-27
    Completion
    2020-11-18
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Autonomic Imbalance; Cancer Survivorship
    InterventionIvabradine; Placebo Oral Tablet
    PhasePhase 2
    Registry statusTerminated

  • Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine

    NCT03367026 · start 2018-01-01

    Registered record
    Registry ID
    NCT03367026
    Conditions
    Sepsis, Severe
    Interventions
    Ivabradine Oral Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2021-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis, Severe
    InterventionIvabradine Oral Product
    PhaseNot applicable
    Registry statusUnknown

  • A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

    NCT03456856 · start 2017-09-28

    Registered record
    Registry ID
    NCT03456856
    Conditions
    Heart Failure (HF)
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-28
    Completion
    2019-05-20
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    InterventionIvabradine
    PhasePhase 4
    Registry statusCompleted

  • The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

    NCT04217135 · start 2017-01-01

    Registered record
    Registry ID
    NCT04217135
    Conditions
    Systolic Heart Failure Stage D (Disorder); Mitral Regurgitation
    Interventions
    evidence-based medications vs. high-dose hydralazine + evidence-based medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-01-01
    Completion
    2022-07-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystolic Heart Failure Stage D (Disorder); Mitral Regurgitation
    Interventionevidence-based medications vs. high-dose hydralazine + evidence-based medications
    PhasePhase 4
    Registry statusUnknown